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Abstract 
Cells are basic functional components of eukaryotic organisms containing rich biological and 
physiological information. To investigate the nature of cells, a variety of fundamental and 
mechanistic studies of the cell functions, cellular metabolisms, metabolomic pathways, cell-cell 
interactions, and the interaction between cells and the surrounding microenvironment, to name a 
few, were conducted in recent years. Besides considerable achievements, cell-to-cell 
heterogeneity was recognized as the intrinsic property of cells, that is, individual cells possess 
unique biological traits different from other cells, even compared with their neighbors of the 
same genotype. Unfortunately, such cell-to-cell heterogeneity is masked by conventional 
analysis at the cell population level, which generally results in an averaged signal of all cells 
analyzed. Therefore, analytical methods that well appreciate the cell heterogeneity are desired to 
investigate cells at a higher resolution, that is, at the single cell level. 
 
However, several major challenges exist in conducting single cell-level studies. First, the volume 
of a single cell is small (i.e., ~10 µm in diameter of a mammalian cell). Due to such dimension, 
the analyte within a single cell is extremely limited. Second, it is difficult to handle single cell 
samples due to the fragile nature of single cells. Third, some cellular species are prone to rapid 
turnover, and therefore, a departure from near-native biological microenvironment. Therefore, in 
this work, an integrated and multifunctional device, the T-probe, was designed and fabricated to 
conduct online and in situ analysis of live single cells at ambient condition in chapter 2. After the 
data acquisition, a comprehensive and generalized data analysis workflow was proposed to 
conduct single cell metabolomics and reveal the underlying biological principals beneath the 
complex raw data matrix in chapter 3. The initial data acquisition and the metabolomic analysis 
viii 
 
were further combined with more advanced data analysis methods such machine learning (ML) 
algorithms using artificial intelligence to handle big data to learn the underlying patterns of 
cellular metabolisms, and ultimately facilitating decision making. In chapter 4 and 5, different 
ML models were constructed based on the acquired datasets of single cells, and evaluated in 
terms of the predictive accuracy of an unknown single cell possessing drug resistance. Rapid and 
reliable predictions of cells possessing primary or drug-induced resistance were demonstrated 
using established ML models on the testing datasets, and the robustness of the model was 
validated through accurate predictions of cells on a different batch. Such results suggested 
promising potential of the ML models towards future point-of-care (POC) prognostic assays. 
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Chapter 1: Introduction 
 
Cell, as the fundamental component of eukaryotic living creatures, carries rich information. 
Among reported analytical approaches such as mass spectrometry (MS),1-3 nuclear magnetic 
resonance (NMR),4,5 Raman spectroscopy,6,7 optical imaging,8,9 and hybrid methods10-12 that 
study cellular properties and investigate the biological nature of cells, MS gains unique 
advantages for its high sensitivity,13 mass resolution14 and throughput15 in interrogations of 
cellular contents. Therefore, a variety of MS-based techniques were proposed and applied 
towards different biological systems to illustrate biological mechanisms,16,17 identify unknown 
species,18,19 and contribute to translational applications.20,21 
 
Among all related research, the study of cellular metabolites that are downstream products of 
upstream regulations by genes,22 transcriptomes23 and proteins,24 becomes an intriguing field, 
metabolomics. In recent years, efforts and contributions were devoted in metabolomic studies to 
enhance the understanding of cellular metabolism.25,26 However, most of those were conducted at 
the populational level, resulting in an averaged signal of the entire cohort. As the cell 
heterogeneity that refers to the inherent difference between each cell due to intrinsic and 
extrinsic factors27,28 was recognized as the key factor in a variety of biological process such as 
differentiation,29 metastasis,30 and drug resistance,31 the investigation of cells at the single cell 
resolution is desired. 
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To date, a collection of MS-based techniques have been developed in the analysis of single cell 
samples, with their working mechanisms illustrated and applications demonstrated in recently 
published review articles.32-36 However, most of those articles heavily focused on the technical 
aspects in data acquisition (i.e., sample preparation and MS detection), rather than the 
methodologies in the metabolomic data analysis process that are of equal importance. Regardless 
of the MS platform (i.e., Orbitrap, QToF, FT-ICR, Ion Trap, etc.) employed to acquire the 
metabolomic information from single cells, the generated raw data set is complex. Therefore, 
efficient data analysis approaches are imperative to analyze and interpret the data set, and further 
gain a profound understanding of the cellular metabolism. Although in this current era, single 
cell metabolomics is still in its infancy and there is a lack of a standard workflow widely 
accepted to process the single cell metabolomic data for all labs, majority of data analysis 
approaches reported were derived from the standard workflow used in the conventional liquid 
chromatography-MS (LC-MS) metabolomics, and therefore, they share some similarities. In this 
review, we focus on the discussion of data analysis approaches including data pretreatment, 
multivariate analysis, univariate analysis and advanced data analysis to gain a biological 
perspective beneath the raw single cell metabolomic data. Especially, we provide an in-depth 
overview of the details in the single cell metabolomics data processing. 
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Figure 1.1. Workflow of SCMS data analysis consisting of data pre-treatment, multivariate 
analysis, and univariate analysis. This generalized procedure can be coupled to raw datasets 
obtained from broader types of SCMS platforms for single cell metabolomic analysis. Figure 
reproduced from Elsevier. 
 
Data pretreatment. Single cell metabolomic data pre-treatment is the starting and essential step to 
extract useful biological information from the raw data and facilitate downstream statistical 
analysis. Referring to a recently published single cell metabolomic data analysis workflow37 as a 
guideline, the data pretreatment generally includes background removal, peak normalization, 
data alignment and common species selection. First, raw data acquired by a variety of MS 
platforms were accessed by vendor-specific software (e.g., Xcalibur,37,38 MassLynx,39 Compass 
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Data Analysis,40 etc.), followed by removal of MS peaks corresponding to the background (i.e., 
solvent, ambient culture medium, and other matrix). Such step could be conducted using either 
commercially available software or customized software. In addition, instrument noise that is 
considered random could be removed by eliminating MS peaks of lower abundance. By 
removing the background and instrument noise, MS signals corresponding to endogenous 
cellular metabolites were readily retained. Second, peak normalization was conducted to 
normalize the MS signals harvested from each individual cell to eliminate the difference of the 
absolute amount of analyte contained in each cell. Generally, the normalization was conducted 
by normalizing all peaks to the total ion current (TIC) in modern single cell metabolomic data 
analysis procedures. However, other normalization methods (i.e., normalizing to the base peak) 
could be suitable in particular cases. Third, MS peaks were aligned among all measured cells, 
followed by the selection of the missing value threshold (%) to include a portion of the processed 
data containing an acceptable level of non-zero values for downstream analysis. Although the 
selection criterion for the missing value threshold was not standard, adopting an appropriate level 
(i.e., < 50%)38,41 is critical for convincing results. Last, selected variables (metabolites) along 
with their relative intensities were subjected to mean-centering and scaling (e.g., Auto or Pareto) 
to smooth the data distribution prior to downstream statistical analysis. 
 
Multivariate analysis. Based on the pretreated single cell metabolomic data that contain multiple 
variables (metabolic species represented by their m/z values and the corresponding relative ion 
intensities), multivariate analysis was routinely performed to visualize such high dimensional 
data in lower (i.e., 2D or 3D) dimensional space. A variety of multivariate approaches were 
reported in previous publications to reduce the data dimensionality, and facilitate visualization. 
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In general, those approaches could be classified into two categories, unsupervised (i.e., requiring 
no prior knowledge of the data) and supervised (i.e., requiring some prior knowledge such as the 
grouping attribute of the data). For example, principle component analysis (PCA) and t-
distributed stochastic neighbor embedding (t-sne) are two popular unsupervised methods that 
project high dimensional data in low dimensional space while retaining their features in the 
original space. PCA decomposes the original dataset into a series of orthogonal components (i.e., 
principle components), and projects them to the lower-dimensional space. The corresponding 
data points on the score plot represent the integral cellular profiles, and the difference among 
groups (e.g., different cell types) could be intuitively visualized based on the 95% confidence 
ellipses.42 Despite the score plot, the loading plot contains rich information that can be used to 
distinguish cell subpopulations43 or determine biomarker species characteristic to a certain 
condition.44 Additionally, the distribution of the data points within a group could be used to 
represent the cell-to-cell heterogeneity in recent publications.45-47 On the other hand, t-sne 
utilizes a non-linear function to retain the similarities between adjacent data points in the lower-
dimensional space. Such dimension reduction method has been conducted to visualize cellular 
profiles and determine cell subpopulations.48 However, the underlying mathematical principal for 
these methods is different (i.e., linear vs. non-linear model), therefore, the observed distribution 
of data points on the resulting score plot is different. In present studies, both methods have been 
widely applied and they provide complimentary information with respect to the cellular 
metabolomic profiles as well as similarities between cells under multiple conditions. On the 
contrary, supervised methods such as partial least squares-discriminant analysis (PLS-DA) and 
orthogonal partial least squares-discriminant analysis (OPLS-DA) require input of prior 
knowledge to the data analysis, and usually they outperformed the unsupervised methods in 
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clustering.17,38,49 However, such models tend to be overfitted. Hence, careful model evaluation 
through cross-validation and permutation tests is essential. Again, the corresponding loading plot 
can be used to further reveal biomarker species that significantly contributed to the 
discrimination of different cell groups,49-51 and the variable importance of projection (VIP) 
values could be used to indicate metabolic biomarkers.37,38,52 
 
Figure 1.2. (A) PCA and (B) PLS-DA score plots of cellular profiles of Coscinodiscus granii 
strain SCCAP-K1834 and isolate Helg2016 recovered from early (Day 1) and late (Day 15) 
growth stages. An evident discrimination between SCCAP-K1834 Day 1 and SCCAP-K1834 
Day 15 can be observed only in the PLS-DA plot. Figure reproduced from Frontiers. 
 
Univariate analysis. The primary purpose of univariate analysis is to discover cellular species 
with significant change in abundance (i.e., metabolic biomarkers) among a series of groups 
compared. Standard statistical approaches including t-test and analysis of variance (ANOVA) 
were frequently used between two-group and among multi-group comparison, respectively. 
However, due to the unique nature of the single cell metabolomic data, the data distribution may 
be distorted, and the homogeneity of variance may be disturbed among groups to be compared. 
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Therefore, more rigorous statistical approaches should be conducted. For example, data 
transformation (i.e., generalized log transformation) was conducted to correct and approximate 
the data distribution to Gaussian or near-Gaussian, followed by the Levene’s test to determine 
the type of statistical analysis (i.e., parametric or non-parametric) to be performed. Based on the 
testing statistic of the Levene’s test, Student’s or Welch’s t-test can be performed using each 
variable in a two-group comparison setting; whereas one-way or Welch’s ANOVA can be 
performed in a multi-group comparison setting. In case the data distribution is highly skewed, a 
non-parametric Mann-Whitley U test (for two groups)48,53 or Kruskal-Wallis H test (for multiple 
groups)54 can be performed. A confidence level of 95% (α = 0.05) was constantly reported for 
single cell metabolomic studies, and the false discover rate (FDR) correction was generally 
adopted when performing multiple statistical tests to reduce the false discover rate.52 
 
Pathway topology analysis. Similar to conventional LC-MS, the pathway topology analysis can 
be conducted by computing significantly altered or enriched pathways using the relative 
intensities of identified metabolites. Those significantly altered pathways revealed at the single 
cell level could be further mapped against a global biological system (e.g., zebrafish)55 to 
generate a holistic picture of the metabolic activities.56,57 More recently, bioinformatics tools 
such as Mummichog was released to compute for altered pathways using only the full MS data 
acquired from single cells,37 paving a new avenue for future shotgun metabolomics/lipidomics 
studies at the single cell level. 
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Figure 1.3. Pathway analysis for metabolites with asymmetric distribution between left and right 
D1 blastomeres. Correlation between p value from pathway enrichment analysis and pathway 
impact from pathway topology analysis in MetaboAnalyst identified arginine–proline as the most 
represented pathway (left panel). Identified metabolites underlying this pathway were mapped 
against KEGG using Danio rerio (zebrafish) as the model organism (right panel). Reproduced 
from The Royal Society of Chemistry. 
 
Advanced data analysis. Despite conventional multivariate and univariate data analysis methods, 
advanced methods have emerged and been incorporated into the single cell metabolomic data 
analysis workflow. For example, machine learning (ML) algorithms that utilize artificial 
intelligence to handle big data have been introduced not only in LC-MS metabolomic research,58 
also recently in the single cell metabolomic studies.37,44 With the introduction of different ML 
methods, subtle patterns or trends not intuitive to the human eyes can be revealed and discerned. 
For example, random forest (RF), logistic regression (LR) and artificial neural network (ANN) 
were used to construct ML models capable of predicting the attribute (i.e., primary drug 
resistance) of unknown single cells based on the cellular metabolomic profiles rapidly with high 
accuracy.44 Those reported models showed promising potentials to be applied towards future 
point-of-care diagnostic assays. 
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Figure 1.4. Workflow of the combined single cell mass spectrometry experiments and machine 
learning (ML) data analysis methods. (A) MS measurements of single cells using the single-
probe SCMS technique. (B) A comprehensive data processing approach to extract metabolomic 
information from raw SCMS datasets and visualize cellular profiles in low dimensional space. 
(C) ML models built on cells with two different phenotypes (with or without CAM-DR). (D) 
Rapid and reliable prediction of drug-resistant phenotypes at the single cell level. Reproduced by 
permission of The Royal Society of Chemistry. 
 
Evaluation of technical and biological variance. Due to the cell heterogeneity, fluctuation of MS 
signals and the destructive nature of some sampling methods, the technical (i.e., difference of 
measured signals induced by extrinsic factors such as instrumental stability, random error, etc.) 
and biological (i.e., difference of measured signals induced by the biological nature of the 
sample) variance were usually evaluated as an experimental validation. To date, multiple 
evaluations were conducted using different sampling devices on a variety of biological systems, 
and consistently, they demonstrated the dominance of biological variance among single cell 
metabolomic datasets.41,51,53 
10 
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Chapter 2: T-Probe: An Integrated Microscale Device for Online In Situ Single Cell Analysis 
and Metabolic Profiling Using Mass Spectrometry 
 
2.1. Introduction 
Cell, as a basic component of living organisms, contains rich biological information such as 
expression of genes,1 interaction with other cells,2 and metabolic response to altered 
microenvironment.3 Numerous techniques have been dedicatedly developed to study cellular 
constituents and reveal the biological principles of cellular metabolism.4-7 Mass spectrometry 
(MS), a rapidly developing technique to analyze ion species with high accuracy and sensitivity, 
stands out as a powerful tool to achieve efficient and reliable analysis of cell extractions.8-10 
Conventional MS-based methodologies, such as the analysis of cell lysate using LC (liquid 
chromatography)-MS, have been broadly adopted in studies of populations of cells, and 
consequently resulted in averaged chemical information from cell populations analyzed.11-14 In 
fact, cells are unique individuals that present heterogeneity due to intrinsic (e.g., genetic 
information) and extrinsic (e.g., surrounding microenvironment) factors.15 To overcome 
drawbacks of the conventional methods and obtain biological signature of individual cells, a 
number of MS based techniques have been developed to conduct single cell MS (SCMS) analysis. 
Depending on the sampling mechanisms, these methods can be generally classified as ion beam-
based, laser-based, probe-based, and other methods. Ion beam-based SCMS methods primarily 
refer to secondary ion MS (SIMS), which provides high special resolution, allowing for subcellular 
analysis.16-17 Laser-based SCMS methods include but are not limited to matrix assisted laser 
desorption/ionization (MALDI) MS, laser ablation electrospray ionization (LAESI) MS, and laser 
desorption/ionization on porous silicon (DIOS) MS. MALDI MS is a popular method to achieve 
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tissue level and single cell level analyses with high resolution and throughput.18-20 LAESI MS, as 
an ambient SCMS method that allows for studies of live cells with minimum sample preparation, 
has been successfully applied to analyze a large variety of cell lines in situ.21-23 DIOS MS is an 
alternative ambient SCMS method, which allows cells to be cultured directly on porous silicon 
substrates followed by laser ablation and MS detection.24 Probe-based ambient SCMS methods 
include live single cell video MS,25-26 probe electrospray ionization (PESI) MS,27 pressure probe 
electrospray ionization (PPESI) MS,28 induced nano-electrospray ionization (InESI) MS,29 and the 
Single-probe MS methods.30-31 In addition to these non-separative methods, separation techniques, 
such as capillary electrophoresis (CE) and ion mobility separation (IMS), have been coupled with 
MS to study left-right patterning of single blastomeres in frog embryos,32-33 and obtain metabolic 
signatures of single human hepatocytes.34  
Despite broad applications reported, the majority of existing SCMS methods are classified as 
offline SCMS methods, because they generally involve multi-step, offline sample preparation 
procedures. However, cellular metabolites shift immediately (in seconds) upon changes of 
surrounding microenvironment,9 and therefore, rapid real-time SCMS techniques are obligatory to 
analyze live single cells. We have previously developed a probe-based SCMS method, the Single-
probe MS, and demonstrated its applications in single cell analysis,30, 35 MS imaging of brain 
tissues,36-37 and MS analysis of live multicellular tumor spheroids.38  
Here, we report the design and application of a novel miniaturized, integrated sampling and 
ionization device, the T-probe, that can be coupled to MS for online in situ live single cell analysis 
and metabolic profiling. As shown in Figure 2.1A, the T-probe has three major components: a 
sampling probe, a solvent-providing capillary, and a nano-ESI emitter. These capillaries are 
sandwiched by two polycarbonate (PC) substrates engraved with T-shaped grooves, and bound 
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through thermal binding. When the T-probe is used to conduct SCMS experiments, the solvent-
providing capillary delivers sampling solvent (e.g., methanol (50%)/water (50%) with 0.1% formic 
acid) from a syringe. A DC voltage is applied to the conductive union and transmitted though the 
solvent to provide an ionization voltage at the nano-ESI emitter (aperture size ~20 μm). Using the 
optimized solvent flow rate (e.g., 0.2 µL/min) and ionization voltage (e.g., ~4 kV), a stable 
electrospray can be observed at the nano-ESI emitter without forming solvent droplets at the 
sampling probe tip. Our experiments demonstrate that a suction force is generated at the sampling 
probe tip to withdraw cellular contents. At the T-junction, the solvent is mixed with cellular 
species, and the mixture is subsequently delivered to the nano-ESI emitter for ionization and MS 
detection (Figure 2.1B). Although the exact mechanism of generating such suction force is unclear, 
this self-aspiration process is likely due to the continuous consumption of solution inside the nano-
ESI emitter, leading to a liquid flow towards the nano-ESI emitter through the capillary action. 
Switching off the ionization voltage immediately resulted in a paused liquid suction from the 
sampling probe, until the ionization voltage was turned on again. Similar phenomena of solvent 
self-aspiration have been observed in other ambient MS methods such as liquid microjunction 
surface sampling probe (LMJ-SSP),39 nano-desorption electrospray ionization (nano-DESI),40 and 
the Single-probe.30 Under the optimized experimental conditions, the T-probe has no efflux of 
solvent from the sampling probe during the analysis of a target cell, minimizing the perturbation 
of the microenvironment of nearby cells to be analyzed. The perturbation of cell’s 
microenvironment in some other sampling methodologies, in which the solvent, heat, or matrices 
is needed, can potentially alter the native biological states of live cells. In addition, the sampling 
probe (with one channel) of the T-probe can be further minimized (e.g., <1 µm), and potentially 
used for subcellular-level analysis of mammalian cells. To provide additional evidence and shed 
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light on the sampling process of the T-probe, we carried out experiments using a prepared solution, 
and estimated the fraction of liquid introduced from the sampling probe to that from the solvent-
providing capillary. 
 
Figure 2.1. Utilizing the T-probe for the SCMS experiments. (A) Photo of a T-probe. Inset: a 
zoomed-in photo of the sampling probe tip. (B) Illustration of working mechanism and fluid flow 
directions in the T-probe. (C) Components of the T-probe SCMS experimental setup. (D) A photo 
illustrating the insertion of the T-probe tip into a cell.   
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Coupled to a mass spectrometer, the T-probe allows for online in situ MS analysis of live single 
cells in real time with minimal sample preparation. Due to its high sensitivity, the T-probe was 
applied to the detection of a variety of species present in single cells such as endogenous cellular 
metabolites, environmental stimulus (i.e., anticancer drug), and xenobiotic metabolites. Among 
those, we performed online MS/MS analysis for abundant species of interest to confirm their 
chemical identities. In addition, we established a comprehensive MS data analysis approach, 
including multivariate and univariate methods, to perform metabolic profiling at single cell level. 
As a result, we illustrated cellular response to drug treatment and discovered cellular species 
sensitive to such microenvironmental alternation. 
 
 
Figure 2.2. Semi-automated fabrication workflow of the T-probe. (1) The T-shaped grooves are 
engraved on a polycarbonate (PC) substrate using computer numeric control (CNC) 
micromachining. (2) PC slides are cut and (3) subjected to surface silconization treatment. (4) 
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Three capillaries are positioned within grooves and sandwiched by a pristine PC piece. (5) The 
sandwiched assembly is heated in an oven for thermal binding. 
 
2.2. Fabrication of the T-probe 
We developed a semi-automated fabrication protocol to manufacture T-probes with high 
reproducibility and efficiency as demonstrated in Figure 2.2. The fabrication workflow includes 
five major steps. (1) We engraved multiple sets of T-shaped grooves (width ~150 μm) on one PC 
substrate using a computer numeric control (CNC) micro-engraver. (2) A mini electric cutting saw 
was used to cut the engraved PC substrate into individual pieces (each piece contains one set of T-
grooves). The pristine PC substrates (i.e., not engraved) were also cut into pieces with identical 
dimensions. Both engraved and pristine PC substrates were ultrasonically cleaned in iso-propanol 
to remove any residual debris within the grooves and contamination on surfaces. (3) Those cleaned 
PC substrates were dried and then treated with Bis[3-(trimethoxysilyl)propyl]amine (Bis-TPA), a 
siliconization reagent, to increase hydrophilicity of PC surfaces and enhance PC–PC binding in 
the following thermal binding step.41 (4) Three capillaries (i.e., a solvent-providing capillary, a 
sampling probe, and a nano-ESI emitter) were produced from the same type of fused silica 
capillary (O.D. = 150 μm, I.D. = 75 μm). Among them, the sampling probe and the nano-ESI 
emitter were pulled using a laser micro pipette puller (Model P-2000, Sutter Instrument, Novato, 
CA). To fabricate a T-probe, these three capillaries were carefully positioned in grooves on an 
engraved PC substrate. The solvent-providing capillary and the nano-ESI emitter were aligned in-
line, whereas the sampling probe was vertically placed so that they formed a T-junction. A pristine 
PC slide was used to sandwich these three capillaries to form a unit. To retain the positions of 
capillaries and PC slides, we used two glass slides and applied pressure using two paper clippers. 
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(5) Lastly, we kept the sandwiched assembly in an oven at 110 C for 30 min, and two PC slides 
were bound to form a T-probe through thermal binding. With enhanced PC–PC binding strength, 
solvent leakage from T-probes was rarely observed during the following SCMS experiments. 
Moreover, the employment of CNC micromachining promotes our manufacture reproducibility 
and efficiency. These standardized T-probe fabrication protocols can be readily adopted by other 
labs or industrial manufacturing facilities. In addition, the relevant techniques (e.g., 
micromachining, hydrophobic treatment PC surface, and thermal binding process) are valuable for 
studies using plastic microfluidic devices. 
 
2.3. SCMS Experiments Using the T-probe 
The experimental setup for SCMS analysis using the T-probe was adapted from our Single-probe 
SCMS setup.  The T-probe was attached to a manual XYZ-manipulator for position adjustment. 
The nano-ESI emitter was ~2 mm away from the mass spectrometer inlet, and the solvent-
providing capillary was connected to a syringe through a conductive union, where the ionization 
voltage was applied. A glass coverslip containing live HeLa cells and culture medium was placed 
onto a motorized XYZ-translational stage system controlled by a LabView package.42 Two 
microscopes were utilized to monitor the working status of the T-probe: a lateral microscope 
focusing on the nano-ESI emitter of the T-probe to monitor its electrospray conditions, and a stereo 
microscope focusing on the sampling probe tip to monitor the cell sampling process. During SCMS 
experiments, the sampling solvent was continuously delivered through the solvent-providing 
capillary, and stable signals of solvent ions were obtained without solvent dripping from the 
sampling probe by carefully adjusting the solvent flow rate and ionization voltage. We then 
selected a target single cell by moving the motorized XYZ-translational stage so that both the cell 
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and the sampling probe tip were clearly observed under the stereo microscope. By gradually lifting 
the stage (at an increment of 0.1 μm), the sampling probe tip was first submerged into culture 
medium above cells, and then penetrated the cell membrane with a continuous suction. Cellular 
contents along with the surrounding culture medium were subsequently withdrawn into the 
sampling probe and immediately ionized by nano-ESI emitter for MS analysis. Correspondingly, 
we observed dramatic changes of mass spectra profiles from the solvent background through 
culture medium to the mixed cellular constituents and culture medium. Upon finishing the 
measurement of a cell, we lowered down the translational stage to remove the sampling probe tip 
out of the cell. Meanwhile, due to the loss of cytoplasmic contents, a significant change of cell 
morphology was observed under the microscope, and the cell was unlikely viable. To eliminate 
residues (carry-overs) from the sampled cell, we rinsed the T-probe by gently flushing it with the 
sampling solvent while monitoring the MS signal change. Such process ensured cleanness of the 
T-probe prior to the analysis of the next cell. A Thermo LTQ Orbitrap XL mass spectrometer was 
employed in our SCMS data acquisition process for high sensitivity and mass resolution. The 
experimental mass analyze parameters are listed as follows: mass resolution 60,000 at m/z 400, 
mass range 200–1500, +4 kV ionization voltage, 1 microscan, 100 ms max injection time and AGC 
(automatic gain control) on. 
 
2.4. SCMS Data Analysis 
Generally, ion signals corresponding to cellular metabolites were extracted from the raw data, 
whereas background signals (from exogenous species such as cell culture medium and sampling 
solvent) and instrument noise were removed. We carried out Orthogonal Partial Least Squares-
Discriminant Analysis (OPLS-DA)43 in combination with univariate analysis (e.g., two-sample t-
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test) to study changes of cellular profiles induced by drug treatment. We determined cellular 
species with significant abundance change after drug treatment, which are of potential interest of 
clinical and pharmaceutical studies. Lastly, by referring to available online metabolome database 
such as METLIN (https://metlin.scripps.edu)44 and HMDB (http://www.hmdb.ca),45 we 
accomplished tentative labeling for detected species, and further identified (through online MS/MS 
at single cell level) abundant species by comparing their fragmentation patterns with in silico data 
from online database. 
 
2.5. Estimation of Mixing Ratio at the T-junction 
To gain a better understanding of the working mechanism of the T-probe, we estimated the volume 
mixing ratio of cellular contents withdrawn by the sampling probe to the sampling solvent 
delivered from the solvent-providing capillary. Considering the viscosity of cell cytoplasm (2–3 
cP),46 we prepared 250 nM deuterated irinotecan (d10-irinotecan) solution in iso-propanol 
(viscosity = 2.86 cP) in a vial  located underneath the T-probe, whereas regular irinotecan with the 
same concentration was prepared in the sampling solvent (methanol (50%)/water (50%) with 0.1% 
formic acid). In the following experiment, the sampling solution was continuously delivered 
through the solvent-providing capillary at the flow rate used in our SCMS experiment (0.2 
µL/min). Upon applying the ionization voltage, the protonated irinotecan ([irinotecan + H]+) was 
observed. We then submerged the sampling probe tip into the vial containing d10-irinotecan, and 
observed both [irinotecan + H]+ and [d10-irinotecan + H]+. The volume mixing fraction was 
estimated by calculating the relative ion intensities of [irinotecan + H]+ to [d10-irinotecan + H]+. 
Such process was repeated for 5 times, and we found 41.8% ± 1.4% (mean ± standard deviation) 
volume of solution was drawn through the sampling probe. Our experimental results indicate that 
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a sufficient suction is produced at the tip of the sampling probe, and a dilution of extracted cellular 
contents with the sampling solvent occurs at the T-junction, which promotes detection sensitivity.47 
However, it is worth noting that the volume mixing ratio may vary among individual T-probes in 
SCMS experiments, and further studies, such as computational fluid dynamics (CFD) simulations, 
need to be carried out in future work.   
 
2.6. Limit of Detections (LODs) of the T-probe 
To evaluate the sensitivity of the T-probe in MS experiments, we used both the standard nano-
ESI ion source and the T-probe device to measure the prepared solutions and determine their 
LODs, which are defined as the minimum concentrations allowing for MS detection with 
obvious ion signal intensities (i.e., signal-to-noise (S/N) > 3). We selected four standard 
compounds relevant to our SCMS experiments, including cellular lipids 1-oleoyl-2-palmitoyl-sn-
glycero-3-phosphocholine (PC(18:1/16:0)) and 1,3-dihexadecanoyl-2-(9Z-octadecenoyl)-
glycerol (TG(16:0/18:1/16:0)), anticancer drug irinotecan, and a peptide example leucine 
encephalin, to conduct LODs determination. Our results (Table 2.1) indicate that the T-probe 
device exhibits comparable LODs as the standard nano-ESI method. In addition, the LOD of the 
T-probe is comparable to that of the Single-probe (e.g., the LOD of PC(18:1/16:0) is 5 nM).31 
Table 2.1. LODs (nM) of standard compounds detected by nano-ESI and the T-probe. 
Compound Nano-ESI T-probe 
Irinotecan 0.1 0.1 
Leucine 
Enkephalin 
0.8 1.0 
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PC (18:1/16:0) 5.0 10.0 
TG 
(16:0/18:1/16:0) 
0.1 0.1 
 
2.7. SCMS Experiments of Cells under Control Condition  
The T-probe was used to obtain cellular profiles of randomly selected HeLa cells under control 
condition (without drug treatment). The ion signals of cellular species were observed within 
seconds upon the insertion of the sampling probe tip into a cell. Typically, the ion signals from one 
cell could last for > 15 s before a rapid decrease, providing sufficient time to conduct online 
MS/MS analysis of abundant species. Due to the robustness of the T-probe, multiple cells can be 
consecutively measured using one T-probe without changing the device, which paves the way 
towards high throughput SCMS analysis. We tentatively labelled the detected cellular species 
based on their accurate m/z values. According to the tentative labeling, a broad range of cellular 
metabolites, including organic acids, cholesteryl esters (CE), phosphatidylcholines (PC), 
phosphatidylethanolamides (PE), and triglycerides (TG) in their protonated, sodiated, and 
potassiated forms (Figure 2.3A) were present in single cells. It is worth noting that these tentative 
labels are based on the accurate m/z measurement. They are not regarded as identifications, and 
therefore, can be only used as the reference to screen for molecules of interest. Compared with 
previously published studies of single HeLa cells,30-31, 48 our current results show a comparable 
number of lipid species at a higher mass range (i.e., m/z 600−900). While at a lower mass range 
(i.e., m/z 200−600), our method provides more coverage of cellular metabolites (e.g. organic acids) 
than those obtained using other methods (e.g., the Single-probe MS and MALDI-MS). For ions 
with high abundances, such as [PC(34:1) + Na]+ (m/z 782.5676) and [PC(36:2) + Na]+ (m/z 
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808.5832), online in situ MS/MS spectra were obtained though collision-induced dissociation 
(CID) tandem mass spectrometry (MS/MS) to confirm their molecular structures at single cell 
level. Due to the extremely small volume of one HeLa cell (1.2–4.3 pL)49 and the influence of 
matrix effect on ionization (e.g., culture medium extracted along with cellular species suppresses 
the ionization efficiency), it is very challenging to acquire a large number of abundant cellular 
species for MS/MS analysis. Improvement of the current technologies, such as combining with 
microseparation (e.g., capillary electrophoresis) or post-ionization separation (e.g., ion mobility 
separation) methods, is needed to enhance both the coverage and identification of metabolites.  
2.8. SCMS Experiments of Cells under Drug Treatment Condition  
The SCMS experiments were also carried out using cells treated with irinotecan (7-ethyl-10-[4-(1-
piperidino)-1-piperidino]-carbonyloxy camptothecin), which is known as a Topoisomerase  
(Topo-) inhibitor that damages the replication and transcription processes of single strand DNAs 
and ultimately induces cell apoptosis.50 In our experiments, HeLa cells were treated with irinotecan 
under a series of concentrations (i.e., 10 μM, 1 μM, 100 nM, and 10 nM) for 1 h, and then rinsed 
using fresh cell culture medium to remove drug molecules in extracellular medium. We performed 
SCMS analysis and detected the protonated species, [irinotecan + H]+ (m/z 587.2870), in all drug 
treated single cells (Figure 2.3D). Furthermore, the detection of this drug target was confirmed by 
online MS/MS analysis at single cell level. As we decreased the treatment concentration of 
irinotecan, the ion intensity of this drug target markedly decreased. For example, [irinotecan + H]+ 
detected from cells treated with 10 nM irinotecan presented a low signal intensity (S/N ~4) that is 
slightly above its LOD (Figure 2.3D). We then explored cellular xenobiotic activities in response 
to drug stimulus. Particularly, we detected related drug metabolites including decarboxyl-
irinotecan (m/z 543.2971), dehydro-irinotecan (m/z 585.2713), and hydroxyl-irinotecan (m/z 
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603.2819) from single cells. Our findings are in good agreement with previous results, as those 
metabolites were reported in other studies of multicellular spheroids treated using the same drug 
compound.38, 51 It is worth noting that these drug metabolites were observed from single cells 
treated using 10 μM irinotecan, but they were not detected from cells under lower treatment 
concentrations (i.e., 1 μM, 100 nM, and 10 nM). The missing drug metabolites from single cells 
under low-concentration treatment conditions are likely attributed to multiple factors, including 
limited uptake of drug molecules with lower initial dosage,52 insufficient treatment time to develop 
xenobiotic activities,53 and matrix effect (i.e., due to mixed cellular metabolites and species in the 
culture medium) in MS measurements.54 
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Figure 2.3. Mass spectra obtained from SCMS experiments using the T-probe device. (A) A 
zoomed-in view of tentatively labeled cellular species in a mass range of m/z = 700–900. (B–E) 
Metabolic profiles of single cells treated for 1 h using irinotecan at concentrations: (B) 10 µM, (C) 
1 µM, (D) 100 nM, and (E) 10 nM. Drug target is highlighted in red. 
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2.9. Changes of Metabolic Profiles after Drug Treatment 
We conducted SCMS data analysis to gain biological insights into cellular response to the altered 
microenvironment due to drug treatment. Generally, we obtained SCMS data sets from both the 
control (9 cells) and the drug treatment group (11 cells, treated using 1 μM irinotecan for 1 h), and 
performed multivariate and univariate analyses. Typically, we applied OPLS-DA to illustrate group 
discrimination and visualize high dimensional cellular profiles in lower dimensional space, as 
shown on the OPLS-DA score plot (Figure 2.4A). The statistical rationale behind this approach is 
that the between-group variation (i.e., differences of cellular profile between control and treatment 
group) is represented by the predictive component T[1], whereas the within-group variation 
(rendered by cell-to-cell heterogeneity) is represented by the orthogonal component To[1].55 A 
decent separation between cells from two groups can be achieved, indicating cellular profiles were 
significantly altered by drug treatment. The visualized separation obtained from the OPLS-DA 
model was well explained by the variation of each orthogonal component (R2X(cum) = 0.798, 
R2Y(cum) = 0.973) with high predictive ability (Q2(cum) = 0.701). We further performed 
permutation tests56 for the established model to evaluate the potential for model overfitting. Our 
results suggest that irinotecan treatment can induce a rapid change of cellular profiles (e.g., within 
1 h upon treatment),57 and our model has no overfitting.  
In addition to the shifted metabolic profiles, we further discovered a number of cellular species 
with both high variable magnitude (p[1]) and high reliability (p(corr)[1]) in the corresponding 
loading plot (S-plot, Figure 2.4B). These species located on both “wings” of the loading plot have 
major contributions to the observed groups separation,58 and therefore, they are species sensitive 
to drug treatment and can be regarded as potential biomarkers reflecting the treatment efficacy.59 
We performed two-sample t-test for each metabolite and we found 17 species with testing p-values 
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< 0.05 (as marked in Figure 2.4B), indicating statistically significant change of abundance due to 
drug treatment. Among those, the protonated pyridoxamine-5’-phosphate ([PMP + H]+, m/z 
249.0640, shown in Figure 2.3B) and sodiated nicotinamide adenine dinucleotide ([NAD + Na]+, 
m/z 686.0989, shown in Figure 2.3C) were detected along with other common cellular species. 
They were tentatively assigned with relatively high confidence using the combined information 
such as accurate mass, isotopic distribution, and database search. PMP is a precursor of pyridoxal-
5’-phosphate (PLP), a coenzyme regulating a variety of intracellular pathways, and it was reported 
as a biomarker of cancer risk.60 NAD, as a coenzyme that maintains energy homeostasis and 
mediates cell signaling pathways, was reported to be a pharmaceutical target for cancer 
treatment.61-62 Our findings suggest that cellular metabolites, such as PMP and NAD, can be 
closely monitored upon irinotecan treatment at single cell level, and they may be potential 
biomarkers to indicate drug efficacy (inset of Figure 2.4B).  
 
Figure 2.4. Multivariate analysis of metabolic profiles of single cells using OPLS-DA. (A) Score 
plot of OPLS-DA model shows group separation between the control and drug treated single cells 
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(T[1]) as well as intrinsic cell-to-cell heterogeneity (To[1]). (B) Loading plot (S-plot) of OPLS-
DA model indicates cellular species significantly changed by drug treatment (primarily located on 
two “wings” of the S-plot). These species were revealed using two sample t-test and numbered as 
1–17. Inset: box plots of two tentatively assigned species (PMP and NAD) present significant 
abundance changes (t-test p-value < 0.05) upon drug treatment.  
 
2.10. Conclusion 
We designed and fabricated a microscale multifunctional device, the T-probe, to facilitate online 
in situ SCMS analysis and metabolic profiling at single cell level in ambient conditions. We 
demonstrated high sensitivity of the T-probe in SCMS analysis, and interrogated cellular contents 
using our in-house developed platform. Metabolic profiles of single HeLa cells under control and 
a series of drug treatment conditions were obtained and compared. In addition, online MS/MS 
analyses were performed to identify abundant species of interest (i.e., cellular metabolites, drug 
target). We observed that metabolic profiles of cells were significantly changed by the treatment 
of anticancer drug irinotecan, and discovered cellular species sensitive to drug treatment using 
statistical analyses. Those species, among which are PMP and NAD, can be potentially used as 
early prognostic indicators for treatment efficacy, and arouse a great interest in biological and 
pharmaceutical studies. In the future, the T-probe can be potentially coupled with broader types of 
ambient MS instruments to study fundamental cell biology, perform single cell metabolomics, and 
develop novel chemotherapies at single cell or even subcellular level. 
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Chapter 3: Integrating a Generalized Data Analysis Workflow with the Single-probe Mass 
Spectrometry Experiment for Single Cell Metabolomics 
 
3.1. Introduction 
      Cell, as a fundamental component of living organisms, regulates cellular metabolic activities 
through a variety of biological pathways.1,2 In recent years, a tremendous number of metabolites 
that participate in rapid and subtle biological and physiological activities3,4 were intensively 
investigated to gain a profound perspective towards the dynamic nature of the cell.5,6 
Metabolomics, serving as a bridge between cellular metabolism and phenotypes,7,8 becomes an 
increasingly intriguing research field where modern instrumentation and methodologies are 
involved.9,10 Among all techniques for metabolomics studies, mass spectrometry (MS) based 
approaches possess considerable advantages over others for providing a large amount of 
molecular information from complex samples. MS methods are widely used in metabolomic 
studies due to their high sensitivity to detect low-abundance cellular metabolites,11 high mass 
resolution to resolve isobaric species,12 flexible capabilities to be coupled to versatile 
chromatographic separations to enhance metabolite coverage,13,14 and wide selections of 
orthogonal yet compatible analytical methods to discriminant isomers.15,16 To date, the majority 
of current MS based cell metabolomic studies are carried out by analyzing cell lysates prepared 
from a large cohort of cells, and consequently, leading to an accumulative result of populations 
analyzed.17 However, each cell is an individually functional unit that is encoded with 
heterogeneous genomic information, and presents diverse biological status in different 
microenvironment.18 Single cell MS (SCMS), as an emerging field of study, appreciates such 
cell-to-cell heterogeneity masked by conventional liquid chromatography-mass spectrometry 
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(LC-MS) methods through interrogating cellular contents of individual cells. A number of SCMS 
techniques have been dedicatedly developed, and they are roughly classified as ion-beam 
based,19 laser based,20-23 probe based,24-28 and other techniques.29-32 Typically, they have been 
employed for distinguishing cellular fingerprints, identifying intracellular metabolites, and 
discovering new biological mechanisms through single cell metabolomic analysis (i.e., single 
cell metabolomics).33,34 However, to the best of our knowledge, the majority of reported single 
cell metabolomic studies rely on the non-specialized software, which is either vendor-specific 
(MassLynx,35,36 Compass Data Analysis,29,37 etc.) or derived from conventional LC-MS analysis 
(e.g., Decon2LS),38 to process the datasets. Therefore, further efforts are needed to establish the 
standardized data analysis procedure for the single cell metabolomic analysis of data obtained 
from broader types of MS instruments. On the other hand, cells are sensitive to their surrounding 
microenvironment, and cellular metabolites have rapid turnover rate upon subtle changes,39 
which adds another layer of complexity to single cell metabolomics in native status. Facing those 
challenges, it is imperative to develop a comprehensive single cell metabolomics approach 
consisting of SCMS experiments and a generalized pipeline for SCMS metabolomic data 
analysis. Ultimately, a fully developed single cell metabolomics method can be used to capture 
metabolomic signatures of individual cells, identify metabolic phenotypes, and disclose 
underlying biological principles of live single cells. 
      In our single cell metabolomics approach, we used a miniaturized multifunctional sampling 
device, the Single-probe,27,40-45 coupled to MS to analyze live single cells in ambient conditions, 
followed by multivariate and univariate data analysis. We selected human cervical cancer cell 
line, HeLa, as our model system, to demonstrate changes of metabolomic profile of each cell 
upon exposure to external stimuli (i.e., anticancer drugs). Specifically, two types of mitotic 
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inhibitors, paclitaxel (taxol) and vinblastine, were selected for a series of time- and 
concentration-dependent treatments. Both taxol and vinblastine inhibit cell mitotic process in 
G2/M phase by either stabilizing (taxol) or destabilizing (vinblastine) microtubules, and 
ultimately induce cell apoptosis.46,47 Although both drug compounds share similarities such as 
the binding target (microtubules) and IC50 values,
48 their influence on the cellular metabolism 
needs to be further understood at the single cell level.  
      Similar to the untargeted LC-MS metabolomics data handling procedures, our SCMS 
metabolomic data processing aims to discriminate metabolic phenotypes, discover phenotypic 
biomarkers (i.e., characteristic species closely related to specific phenotypes), and unveil related 
biological pathways. However, due to the nature of cell heterogeneity, each cell may have a 
different response to drug treatment resulting in varied metabolomic profiles. Therefore, it is 
impractical to directly apply the conventional metabolomic data analysis procedure to SCMS 
datasets, as the underlying assumption (i.e., homogeneity of variance) of a variety of statistical 
tests are challenged. Here, we developed a comprehensive approach to SCMS metabolomics 
studies by performing data pre-treatment, visualization, statistical analysis, machine learning, 
and pathway enrichment analysis (Figure 3.1). 
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Figure 3.1. Workflow of SCMS data analysis consisting of data pre-treatment, multivariate 
analysis, and univariate analysis. This generalized procedure can be coupled to raw datasets 
obtained from broader types of SCMS platforms for single cell metabolomic analysis.  
3.2. SCMS data acquisition  
      Detailed fabrication procedure and working mechanisms of the Single-probe device are 
provided in our previous publications.27,40 To conduct the SCMS experiment, the Single-probe 
device is coupled to a Thermo LTQ Orbitrap XL mass spectrometer. The tip (size < 10 µm) of 
the Single-probe is inserted into a target cell to extract cellular contents through a liquid junction 
at the probe tip, and then the extracted mixture is driven towards the nano-ESI emitter for 
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immediate ionization and MS detection (Figure 3.2B). Cell selection and penetration are 
precisely controlled by our in-house built XYZ-translational stage system (Figure 3.2A), and 
these processes are visualized using a stereo microscope (Figure 3.2C). The experimental MS 
parameters are listed as follows: ionization voltage +4.5 kV, mass range 150–1500 m/z (mass-to-
charge ratio), mass resolution 60,000 at m/z 400, 1 microscan, and 100 ms max injection time 
and automatic gain control (AGC) on. 
Table 3.1. HeLa cells in the control and treatment groups for SCMS experiments. 
Condition Drug 
Concentration 
(µM) 
Time (h) 
Group 
Name 
Number of 
Cells 
Control N/A N/A N/A Control 23 
 
 
 
Treatment 
 0.1  2  TaxA 25 
Taxol 0.1 6  TaxB 28 
 1.0 2 TaxC 22 
 0.1 2 VinA 28 
Vinblastine 0.1 6 VinB 23 
 1.0 2 VinC 24 
 
To study changes of metabolomic profiles of cancer cells induced by taxol and 
vinblastine, we cultured HeLa cells under normal condition (control), and treated them using a 
series of drug treatment conditions (Table 3.1). Individual cells in both control and treatments 
groups were randomly selected for analysis using the Single-probe SCMS technique. We 
carefully designed our treatment conditions allowing for sufficient cellular metabolomic changes 
to be detected, while minimizing other factors (environmental perturbations, mutations, etc.) that 
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could potentially interfere with phenotypic identification. In our experiments, 22–28 cells were 
sampled from the control group and each of those drug treatment groups.  
 
Figure 3.2. Experimental setup of the Single-probe SCMS system. (A) Key components of the 
in-house developed Single-probe SCMS platform. (B) A zoomed-in photo of the Single-probe 
and illustration of its working mechanism. (C) The insertion of the Single-probe tip into a single 
cell monitored using a high-resolution digital stereo microscope during a SCMS experiment. 
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3.3. SCMS data pre-treatment  
      Following online data acquisition, we performed a generalized comprehensive SCMS 
metabolomics data analysis, including multivariate and univariate analysis, to gain biological 
insights into raw data matrices (Figure 3.1). Particularly, to preserve metabolomic information of 
endogenous species from single cells while avoiding interference with other species (exogenous 
species from the sampling environment, detection noise, etc.), we conducted data pre-treatment 
that can be generally divided into three consecutive steps.  
3.3.1. Generation of metabolomic peak list 
      The acquired raw data files (.raw) from our SCMS experiments were accessed using Xcalibur 
3.0 (Thermo Fisher Scientific). A common cellular species with relatively high ion intensity, PC 
(34:1),27 was selected as an indicator of successful MS detection of cellular contents from 
individual cells. We exported an averaged MS spectrum from each cell containing all detected 
peaks (i.e., m/z values) along with their corresponding ion intensities as the metabolic peak list. 
Similar lists of metabolites can be generated from all other major types of MS platforms, 
including quadrupole time-of-flight (qTOF), fourier transform-ion cyclotron resonance (FT-
ICR), and Orbitraps, using vendor-specific software. 
3.3.2.  MS background removal 
      Under our experimental conditions, a raw file typically consists of more than 6,000 distinct 
peaks, which can be attributed to endogenous species (i.e., cellular metabolites), exogeneous 
species (i.e., from surrounding matrix such as cell culture medium and sampling solvent), and 
instrument noise. Based on the data obtained from 10 randomly selected cells, we estimated the 
total ion current (TIC) of exogenous species and noise are ~11 fold higher than that of 
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endogenous species. This result could be attributed to both the extremely limited amount of 
analytes within a single cell (in picoliter range)39,49 and the reduced detection sensitivity due to 
the matrix effect.50 Because only the relative abundances of cellular metabolites from single cells 
were used in the downstream analysis, we excluded interfering ion as described below. First, we 
removed ion signals of exogenous species (i.e., background ion signals), which were detected 
from cell culture medium and the sampling solvent used in SCMS experiments. Second, we 
filtered out instrument noise, which may result in false positive discovery and unnecessary 
computational burden to data analysis. Instrument noise accounts for ~20–40% of the total 
number of peaks detected in SCMS experiments, and it was removed by eliminating ions with 
evidently lower ion intensities (< 103). Removing background and noise greatly reduced the 
dimensionality of SCMS data matrices and preserved the molecular information of endogenous 
cellular metabolites. Lastly, we normalized the ion intensity of each metabolite to TIC prior to 
the following data processing steps. It is worth noting that our background removal method is 
similar to those used in prevalent LC-MS metabolomics data analysis software (e.g., MZmine 2). 
However, discriminating instrument noise from low-abundance MS peaks of cellular metabolites 
is challenging. Other advanced noise removal algorithms, such as repetition rate filtering (RRF) 
that has been demonstrated effective in shotgun lipidomics,51 can be incorporated in future 
studies. 
3.3.3. Peak alignment and common species determination  
      The SCMS datasets obtained from the previous step were submitted to Geena 252 for MS 
peak alignment. We then utilized MetaboAnalyst53,54 to determine the common species, which 
are defined as cellular species that can be frequently detected from measured cells in each group. 
Here, we referred to the standard 80% rule (i.e., excluding species with > 20% missing values 
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from all measured cells), a broadly accepted rule for feature selection in untargeted LC-MS 
metabolomics research,55 as the criterion to determine common species. In addition, a missing 
value imputation (MVI) algorithm, K-nearest neighbor (KNN),56 was employed to eliminate 
missing values and reduce false positive results in our analysis. Using the above data pre-
treatment procedures, we promptly reduced the size of our datasets while retaining the essential 
metabolomic information from individual cells. However, this 80% rule may eliminate rare cells, 
which can be critical for a variety of biological mechanisms present in a large population of 
cells.57,58 To include more measured cells for SCMS data analysis, a lenient missing value 
threshold can be employed. However, applying a loose missing value threshold may reduce the 
statistical power, introduce bias, and increase computing demand.59 
3.4. SCMS data visualization 
      To evaluate the differences of metabolomic profiles of single cells among all groups, we 
conducted the dimensionality reduction of pre-treated SCMS datasets, which facilitates the 
visualization of high-dimensional data matrices in a low-dimensional space through multivariate 
analysis. Here, we employed Partial Least Square-Discriminant Analysis (PLS-DA), a 
supervised method, to achieve phenotypic separation when the within-group variation (i.e., 
variation of cellular metabolite abundance within the control and each of the treatment groups) is 
pronounced.60 To evaluate the quality of PLS-DA models and avoid data overfitting, the 
explained variation (R2) and the predictive ability (Q2) were calculated through a 10-fold cross 
validation procedure.61 PLS-DA models with Q2 > 0.5 were considered to be robust,62 and they 
were further analyzed using permutation tests63 to identify significantly separated phenotypes. 
We performed 2,000 permutation tests for each model, and a small statistic p-value (< 0.05) 
indicated a significant phenotypic discrimination. 
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3.5. Discovery of phenotypic biomarkers 
      To study changes of metabolomic profiles of single cells induced by microenvironmental 
alternation (i.e., drug treatment) and discover phenotypic biomarkers, we utilized statistical 
methods to process SCMS metabolomic datasets after data pre-treatment.  
3.5.1. Biomarkers from pairwise group comparison  
      To discover phenotypic biomarkers corresponding to a particular treatment condition, we 
utilized the pre-treated SCMS datasets from the control group and that treatment group for the 
PLS-DA. We then calculated Variable Importance in Projection (VIP) scores for all cellular 
species, and selected those with VIP scores >1.2, representing major contributions to group 
discrimination,64 as biomarker candidates. These biomarker candidates were subsequently 
subjected to unpaired two-sample t-test for the comparison of abundances. Due to cell 
heterogeneity, cellular response to the drug treatment is different. Therefore, Levene’s test was 
conducted prior to t-test to evaluate the homogeneity of variance of each metabolite, allowing us 
to determine which type of t-test to be performed. Depending on the results from Levene’s test, 
we performed Student’s t-test (data with equal within-group variance) or Welch’s t-test (data 
with unequal within-group variance). Cellular species with both VIP scores > 1.2 and p-value 
(from t-test) < 0.05 were marked as potential biomarkers related to the examined phenotypes.  
3.5.2. Biomarkers from multi-group comparison 
      To obtain common biomarkers reflecting the influence of drug molecules on cellular 
metabolism, we compared the ion abundance of detected species in the control and all treatment 
groups for each drug compound. First, similar to the pairwise group comparison in the previous 
step, we conducted Levene’s test to evaluate the homogeneity of variance for each metabolite 
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among multiple examined groups. Second, to determine if there are statistically significant 
differences of metabolites among all groups, we used one-way (data with equal within-group 
variance) or Welch’s (data with unequal within-group variance) Analysis of Variance (ANOVA). 
Third, to rigorously select biomarkers (i.e., metabolites with significant abundance change), we 
then performed two types of post hoc tests for metabolites with p-value < 0.05 (from ANOVA): 
Tukey’s HSD (Honestly Significant Difference) and Games-Howell tests for one-way ANOVA 
and Welch’s ANOVA tests, respectively. Cellular species with p-values < 0.05 (from both the 
ANOVA and the corresponding post hoc tests) among all examined groups were highlighted as 
biomarkers. The above procedures have been previously used in LC-MS metabolomics studies to 
discover biomarkers corresponding to dyslipidemia progression.65 All above statistical analyses 
were performed in R environment with functions available in Metabox, a toolbox for 
metabolomic studies.66  
3.5.3. Tentative assignment and identification of biomarkers 
      To identify discovered biomarkers, their accurate m/z values were compared with those 
registered at online metabolome database, METLIN67 and HMDB68. Moreover, we performed 
online MS/MS analysis of biomarkers with relatively higher abundance at the single cell level, 
whereas conventional LC-MS/MS experiments were also carried out as a complimentary 
approach to molecular identification at the population level. 
3.6. Potential biological pathways  
      Mummichog, a program for data analysis in untargeted metabolomics studies,69 was used in 
the current work to address potential biological pathways involved in drug treatment at the single 
cell level. Unlike many other available programs, Mummichog only utilizes the information of 
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accurate m/z values, rather than identified metabolites, to perform pathway enrichment 
analysis.70 Required inputs, such as m/z values, t-test p-values, and fold change of all cellular 
species, were fulfilled based on results from the data analysis as described in the previous steps, 
and Mummichog was operated using default settings.  
3.7. Metabolic response to drug treatment  
      To study cellular metabolic response and visualize phenotypic separation induced by drug 
treatment, we constructed PLS-DA models for SCMS datasets collected from the control and 
each of those drug treatment groups. As shown in Figure 3.3, a data point represents the 
metabolomic profile of a single cell, and the cell-to-cell heterogeneity can be reflected by the 
distribution of data points within a group.71,72 The phenotypic separation can be visualized by the 
distance of data points between two groups. Generally, the first PLS-DA component explains 
more than 25% of variance (i.e., Component 1 > 25%) in all score plots, and significant 
phenotypic discrimination (p < 0.0035) between two groups is further demonstrated through 
permutation tests. However, the overlapped regions can still be observed between the control and 
a “shorter” treatment time condition (i.e., TaxA, VinA, TaxC, or VinC) for both drugs. In 
contrast, complete group separation (no overlapped region) can be observed between the control 
and a “longer” treatment time condition (TaxB or VinB). This trend is also visually reflected on 
PLS-DA score plots containing multiple groups, in which a complete phenotypic separation is 
only observed between the control and “longer” treatment time condition. From a biological 
perspective, though cellular xenobiotic activity was reported to be both time- and concentration-
dependent,73 our SCMS results demonstrate that treatment time has a more significant influence 
on cells’ metabolomic profiles, at least at early treatment stage (e.g., treatment time < 6 h). To 
validate our SCMS results, we prepared lysates using cells, which were treated under the same 
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conditions as those in the SCMS experiments, for LC-MS analysis. We further conducted 
principal component analysis (PCA) of the LC-MS results, and obtained similar trends observed 
in the SCMS studies: longer treatment time resulted in more evident changes of cellular 
metabolomic profiles. In addition, we compared the number of metabolites detected using the 
LC-MS and SCMS approaches. As shown in the Venn diagram, 230 cellular metabolites can 
only be detected in the SCMS datasets; these metabolites are likely to have rapid turnover rates, 
and therefore could be potentially lost during the lengthy LC-MS sample preparation process. On 
the other hand, due to significantly larger amounts of cellular species contained in the cell lysate 
and chromatographic separation (i.e., minimized matrix effect) in the LC-MS measurement, 
more metabolites were detected in the LC-MS (1612) than SCMS measurements (340). Thus, 
traditional LC-MS measurements can provide complementary information to our novel SCMS 
studies. 
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Figure 3. PLS-DA score plots in 2D space for phenotypic discrimination between the control and 
a drug treatment group, including (A) TaxA, (B) TaxB, (C) TaxC, (D) VinA, (E) VinB, and (F) 
VinC. Each data point represents the metabolomic profile of an individual cell, and the ellipse 
highlights the 95% confidence region. 
Despite significant phenotypic separation demonstrated by permutation tests for each PLD-DA 
analysis, certain types of uncertainties are regarded as “noise”,74 including cell heterogeneity and 
technical variation (e.g., the sampling process, ionization stability, and instrument condition in 
SCMS experiments), and they may interfere with phenotypic separation in the SCMS data. To 
evaluate the influence of such “noise” on our data analysis, we employed a well-established 
machine learning algorithm in metabolomics studies, random forest,75 to perform phenotypic 
classification. Each pair of pre-treated SCMS datasets were subjected to the classification, and 
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results are summarized in the confusion matrices and pie plots (Figure 3.4). Among them, cells 
in the control and a “shorter” time treatment condition yielded a low misclassification rate (6–
11%, Figures 4A, 4C–4D, and 4F), implying a minor interference of such “noise” on the 
phenotypic separation. More interestingly, the misclassification rate is even lower (0 and 2%, 
Figures 4B and 4E) in the pair of datasets from the control and a “longer” treatment time 
condition, agreeing with the complete separation observed in the PLS-DA score plots (Figure 
3.3). To our best knowledge, this is the first report of employing random forest as an alternative 
approach to evaluate the influence of the “noise”74 on phenotypic separation in single cell 
metabolomics studies. 
 
Figure 4. Cellular species correctly classified (yellow) and misclassified (blue) by random forest 
classification between the control and a drug treatment group, including (A) TaxA, (B) TaxB, 
(C) TaxC, (D) VinA, (E) VinB, and (F) VinC. 
 
3.8. Study of phenotypic biomarkers  
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      As previously reported, the magnitude of the abundance change of cellular metabolites 
represents the degree of difference between phenotypes.76 Therefore, metabolites with significant 
abundances change after drug treatment are suitable candidates for phenotypic biomarkers, and 
they may arise biological interest and further suggest related cellular xenobiotic activities. 
Through our biomarker selection criteria as described above, we discovered a variety of 
phenotypic biomarkers corresponding to multiple treatment conditions, followed by tentative 
assignment of those biomarkers based on accurate mass. To further confirm the chemical 
identities of tentatively labeled biomarkers, we performed MS/MS analysis at the single cell 
level for those with relatively higher ion abundances. Six phenotypic biomarkers, i.e., [PC(16:0) 
+ Na]+ (m/z 518.3194), [PC(18:0) + Na]+ (m/z 546.3506), [SM(34:1) + Na]+ (m/z 725.5539), 
[PC(32:1) + Na]+ (m/z 754.5345), [PC(34:1) + Na]+ (m/z 782.5660), and [PC(36:2) + Na]+ (m/z 
808.5813), were identified from single cells. As a complimentary approach to enhance the 
biomarker identification, LC-MS/MS was also utilized to analyze cell lysates. In addition to the 
above six identified biomarkers, three more identifications, i.e., [PC(34:1) + H]+ (m/z 760.5860), 
[PC(34:2) + Na]+ (m/z 780.5561), and [PC(36:3) + Na]+ (m/z 806.5643), were obtained. The 
majority of the identified biomarkers are phospholipids, which are related to the regulation of 
cell signal transduction in response to external stimuli.77 Heat maps were constructed to 
intuitively visualize the relative abundances of the discovered biomarkers of cells in each 
treatment group (Figures S9 and S10).  The overall color clusters (i.e., red and blue) matched 
well with cell attributes, although slight color variations can be observed for each biomarker 
among multiple cells likely due to cell heterogeneity.  
3.9. Potential biological pathways  
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      As biomarkers are tightly related to biological pathways regulating cellular metabolism,78 we 
used the biomarkers discovered from our SCMS studies to unveil potential biological pathways 
related to metabolomic response to the drug treatment. We found two pathways, biopterin 
metabolism (p-value = 0.025) and glycerophospholipid metabolism (p-value = 0.041), were 
significantly enriched by taxol treatment. Other two pathways, bile acid biosynthesis (p-value = 
0.021) and de novo fatty acid biosynthesis (p-value = 0.043), were significantly enriched by 
vinblastine treatment. The altered biopterin metabolism may be attributed to enzymatic activities 
related to guanosine triphosphate (GTP) cyclohydrolase I, which regulates biopterin 
metabolism79 and is sensitive to drug treatment.80 Glycerophospholipid metabolism involves a 
variety of phospholipids, which are responsible for cellular signal transduction77 sensitive to 
surrounding microenvironment.81 Bile acids are cell signaling molecules that are closely related 
to the regulation of energy and metabolic homeostasis,82 and our SCMS results achieved good 
agreement with previous publications reporting a suppressed bile acid metabolism following 
vinblastine treatment.83 De novo fatty acid biosynthesis has been reported to be suppressed upon 
drug treatment.84 Our results, from the perspective of single cell metabolomics, suggest that 
those biological pathways may be significantly influenced by the treatment of mitotic inhibitors. 
It is worth noting that MS experimental conditions, such as the solvent composition85, ionization 
polarity86, and instrument type and tuning, can affect the detection sensitivity of different classes 
of species. Because our SCMS measurements were conducted under the same condition (i.e., 
using acidified acetonitrile sampling solvent, positive ion mode, and only one model of mass 
spectrometer), metabolites detected in the current study are likely within a limited coverage 
range. Therefore, more comprehensive experimental conditions can be used in future studies for 
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broader coverage of metabolites, and ultimately enhance the statistical power in pathway 
enrichment analysis. 
 
3.10. Conclusion 
      We performed live single cell metabolomics studies using the Single-probe SCMS 
experiments in combination with a generalized comprehensive data analysis procedure. Cellular 
response to two mitotic inhibitors, taxol and vinblastine, were investigated and compared under 
multiple treatment conditions. Through the visualization using PLS-DA and the following 
permutation tests, our SCMS metabolomics results showed a rapid emergence of new 
phenotypes upon drug treatment. Similar trends were observed from traditional LC-MS 
experiments utilizing lysates prepared from population cells treated under the same conditions. 
Phenotypic biomarkers corresponding to two or multiple treatment conditions were discovered 
through statistical tests, with some of those further identified at both single cell and population 
levels. Based on the information of discovered biomarkers, potential biological pathways related 
to drug treatment were unveiled using the pathway enrichment analysis. Our methodology holds 
a promising potential to be readily coupled to other SCMS datasets produced from broader types 
of MS based analytical approaches to implement metabolomics at the single cell level, and 
ultimately gain insights into biological principles that regulate cellular metabolism. 
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Chapter 4: Towards Rapid Prediction of Drug-resistant Cancer Cell Phenotypes: 
Single Cell Mass Spectrometry Combined with Machine Learning 
 
4.1. Introduction 
Drug resistance, a phenomenon that renders tumor evasion of anticancer agents, is regarded 
as the major reason for chemotherapeutic failures.1 In other words, a small population of 
cells capable of surviving from chemo-treatment through complex drug-resistant 
mechanisms, become immune to the original therapy, and eventually induce cancer 
relapse.2 In general, there are two major types of drug resistance: primary and acquired. 
Primary resistance reduces the efficacy of chemotherapies before drug exposure, whereas 
acquired drug resistance develops afterwards.3 Unfortunately, drug resistance cannot be 
monitored or evaluated in advance using common molecular imaging techniques, such as 
positron emission tomography, until accomplishing one or two chemo-treatment cycles in 
modern clinical practice,4 resulting in ineffective treatment accompanied by serious toxicity 
for the patients. In addition, different tumor cells within the same histological region may 
respond differently to chemo-treatment due to intratumor heterogeneity.5 However, 
conventional studies of drug resistance based on cell populations lack the ability to uncover 
biological information masked by such tumor cell heterogeneity. Herein, it is imperative to 
study drug resistance through interrogation and evaluation of individual cells using single-
cell based methodologies. Mass spectrometry (MS) is a fast developing technique with 
broad applications in fundamental science and biomedical studies.6,7 Recent development 
in MS allows for analysis of single cells with limited amount of analytes available (as low 
as in pL range for mammalian cells)8 due to its extraordinary sensitivity, high accuracy, 
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and high throughput. To date, reported single cell MS (SCMS) techniques include but are 
not limited to secondary ion MS (SIMS),9 matrix-assisted laser desorption/ionization 
(MALDI) MS,10 laser ablation electrospray ionization (LAESI) MS,11 live-single cell 
video-MS,12 induced nanoESI MS,13 the Single-probe MS,14 and the T-probe MS.15 Among 
these techniques, the Single-probe MS method stands out as an ambient technique to 
analyze live single cells of interest in situ and in real time with high efficiency and 
reliability.14,16,17  
      On the other hand, cell adhesion-mediated drug resistance (CAM-DR) was reported for 
myelogenous leukemia cells upon adhering to extracellular matrix (ECM), which coexists 
with those leukemic cells in the bone marrow, through integrin-ECM interaction.18 
Interestingly, this cell-ECM interaction confers reduced cell apoptosis upon exposure to 
cytotoxic drugs, and was recognized as one important form of primary drug resistance.19 
Despite the achievements of illustrating related biological mechanisms,20,21 limited effort 
was contributed to predict such drug-resistant phenotype prior to any chemo-treatment, 
exposing patients to the risk of ineffective chemotherapy and associated toxicity. Limited 
studies in this area are likely due to a variety of factors, including 1) the lack of rapid and 
sensitive single cell analytical approaches that can simultaneously unveil phenotypical 
discrimination and intratumor heterogeneity, 2) the shortage of methods for systematic 
metabolomic analysis of single cells to reveal cellular metabolomic profiles associated with 
different phenotypes, and 3) the absence of advanced data mining methods towards rapid 
and reliable prediction.  
      To address those issues, we used the Single-probe SCMS technique to conduct 
metabolomic analysis at single cell level (i.e., single cell metabolomics) of cultured chronic 
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myelogenous leukemia (CML) cells (K-562) and obtain metabolomic information that is 
sensitive to upstream gene expression, protein regulation, and change of surrounding 
microenvironment.22 Data analysis was conducted using machine leaning (ML) algorithms 
to mine the complex metabolomic datasets and unveil hidden biological patterns by 
performing clustering, regression, and prediction.23 To the best of our knowledge, it is the 
first time to combine SCMS experiments with ML models for single cell metabolomics 
studies. Our approach provides a potential solution towards rapid and reliable prediction of 
drug-resistant cancer cell phenotypes (e.g. CAM-DR) based on cellular metabolomic 
profiles.  
 
Figure 4.1. Workflow of the combined single cell mass spectrometry (SCMS) experiments and 
machine learning (ML) data analysis methods. (A) MS measurements of single cells using the 
Single-probe SCMS technique. (B) A comprehensive data processing approach to extract 
metabolomic information from raw SCMS datasets and visualize cellular profiles in low 
dimensional space. (C) ML models built on cells with two different phenotypes (with or without 
CAM-DR). (D) Rapid and reliable prediction of drug-resistant phenotypes at single cell level. 
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4.2. Methods 
      K-562 cell line was used as a model system to demonstrate our strategy as shown in 
Figure 4.1. As a well-established model, this cell line has been previously used to study the 
mechanism of CAM-DR in cancer cells.18-20 We followed the published protocols to 
prepare two different phenotypes.18 In brief, we first coated glass cover slips with 
fibronectin (FN), a major component of ECM,24 and then allowed CML cells (K-562 cell 
line) to interact with FN in the cell culture plate. Cells that can adhere to FN (phenotype I) 
were reported to present CAM-DR compared with those suspended in the culture medium 
(phenotype II).18 We prepared single cells of both phenotypes on the same type of glass 
cover slips. Using a hemocytometer, we estimated that 23.9% ± 5.3% of cells possessed 
CAM-DR in a typical experiment. We then utilized the Single-probe SCMS platform 
(Figure 4.2A) to interrogate individual cells and obtained their corresponding metabolomic 
profiles in real-time analysis (Figure 4.2B). We analyzed 100 and 108 single cells of 
phenotypes I and II, respectively. The raw MS data were subjected to pre-treatment, 
including background removal, noise reduction, peak normalization, and peak alignment. 
The endogenous cellular metabolites along with their relative ion intensities were subjected 
to downstream comprehensive analyses, including statistical analyses and ML predictions. 
 
60 
 
Figure 4.2. (A) Experimental setup of the SCMS platform, which is an integrated system including 
a Single-probe device, a Thermo Orbitrap XL mass spectrometer, two microscopes, and a 
motorized XYZ-stage system. (B) Individual leukemic cells located on the sample plate to be 
analyzed. 
 
4.3. Results 
      To qualitatively evaluate and visualize the difference of metabolomic profiles between 
these two phenotypes, we analyzed the SCMS data using the t-distributed stochastic 
neighbor embedding (t-SNE), an algorithm for dimensionality reduction and visualization 
of data points in a non-linear fashion to achieve subtle group discrimination.25,26 As shown 
on the t-SNE plot (Figure 4.3), an evident discrimination between these two phenotypes 
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can be intuitively observed, although some overlapped data points still exist likely due to 
cell heterogeneity. Our results suggest that the metabolomic profiles of two phenotypes are 
significantly different, which might be attributed to integrin-ECM interaction. With such 
evident discrimination, we further applied ML algorithms to establish models capable of 
predicting cellular phenotypes (i.e., CAM-DR or non-CAM-DR) based on the metabolomic 
profiles of cells.  
      In our study, we constructed ML models using random forest (RF), penalized logistic 
regression (LR), and artificial neural network (ANN) following SCMS data pre-treatment 
as described earlier. RF is an ensemble learning method based on multiple constructed 
decision trees and eventually outputs the averaged decision. Penalized LR builds nonlinear 
relationship between the response variable and independent variables through a logistic 
function, followed by minimizing the impact of less contributing variables. Both RF and 
penalized LR methods have been broadly applied to conventional metabolomic studies 
using liquid chromatography-mass spectrometry (LC-MS)27,28 and single cell RNA-seq 
datasets.29 ANN, as a fast-developing ML method, was inspired by the biological neural 
networks in animal brains. ANN optimizes parameters by learning from the prior 
knowledge, and the optimized model generates predictions through connected units and 
nodes. ANN has been previously applied to sorting single cells based on measured 
biomechanical properties,30 and prediction of patient survival though genomics data.31 
Here, we further expanded the applications of those three methods to the analysis of single 
cell metabolomics datasets obtained from the Single-probe SCMS technique. Specifically, 
we applied RF, penalized LR (i.e., elastic net LR), and ANN to our pre-treated single cell 
metabolomics datasets, evaluated the predictive accuracy of each ML model, and recorded 
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the demanded computing time under each experimental condition. We performed model 
construction, evaluation, and k-fold validation for each ML model. 
 
Figure 4.3. Visualization of cellular metabolomic profiles in two-dimensional space using t-
distributed stochastic neighbor embedding (t-SNE). Phenotypic discrimination between two types 
of cells (phenotype I and II) is evident. 
 
 The pre-treated datasets were randomly shuffled with 80% cells being selected as the 
training set and the remaining 20% being selected as the testing set. The training set was 
used to construct and train ML models, whereas the testing set was used to evaluate the 
model performance. Due to tumor cell heterogeneity and experimental variation, single cell 
metabolomics datasets contain missing values (i.e., undetected cellular metabolites that 
were labelled as in 0 values in SCMS metabolomics datasets) in some SCMS 
measurements. Therefore, we evaluated the model performance according to different 
missing value threshold (MVT) as shown in Figure 4.4. For example, a dataset with 20% 
MVT contains variables (metabolites) that can be detected in at least 80% of all measured 
single cells. As the MVT increases, the number of variables increases accordingly (i.e., 
from 7 to 3232 as the MVT increases from 0% to 90%) in each ML model. A gradually 
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improved predictive accuracy was also observed in all three models (Figure 4.4A–C). 
Notably, a pronounced improvement was observed in predictive accuracy (from 77.1% ± 
10.2% to the highest value of 94.8% ± 4.2%) in the RF model when the MVT was raised 
from 0% to 50%. However, further improvement of predictive accuracy was not observed 
with higher MVTs. Compared with the RF model, both penalized LR and ANN methods 
produced higher predictive accuracy when the MVT was below 40%, whereas comparable 
predictive accuracy was achieved as the MVT exceeded 40%. In addition, the highest 
predictive accuracy (i.e., 94.7% ± 1.8% and 96.2% ± 2.7%) can be obtained at 80% MVT 
for penalized LR and ANN models, respectively. Considering the trade-off between 
predictive accuracy and computing cost, which is a critical factor when handling larger 
sizes of data, we adopted ANN model with 40% MVT for rapid (~ 6 s) and reliable 
prediction (> 95% predictive accuracy) of drug-resistant phenotypes. We further 
demonstrated the predictive power of all ML models (with 40% MVT) in distinguishing 
two phenotypes using receiver operating characteristic (ROC) curve analysis32 that 
examines the sensitivity and specificity of the model (Figure 4.4D–F). Consistently, the 
ANN model is superior in prediction with the area under the curve (AUCANN) = 0.9976 
compared with the other two models (AUCRF = 0.9542 and AUCpenalized LR = 0.9884). To 
experimentally validate our method and evaluate the predictive accuracy of the ANN 
model, we conducted SCMS experiments and data pre-treatment for another batch of 31 
single cells prepared on a different day, and utilized the trained ANN model to predict this 
new set of data. Our results show that the ANN model produced 87.1% ± 4.8% predictive 
accuracy, achieving comparable performance compared with our earlier results on the 
testing set. 
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Figure 4.4. Evaluation of ML models. (A–C) Predictive accuracy of the random forest (RF), 
penalized logistic regression (LR), and artificial neural network (ANN) model were evaluated 
using different missing value thresholds (MVTs). (D–F) Evaluation of the predictive power of the 
corresponding RF, penalized LR, and ANN models using receiver operating characteristic (ROC) 
curve analysis. The area under the curve (AUC) were calculated for all three models. 
 
4.4. Conclusion 
      In conclusion, we reported studies using the combined ambient SCMS technique (i.e., 
the Single-probe MS) and ML models to distinguish and predict drug-resistant phenotypes 
(e.g. CAM-DR) of live single cells through cellular metabolomic profiles for the first time. 
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Previous studies reported a number of prediction methods based on metabolic biomarkers 
(i.e., cellular species characteristic of specific disease, phenotype, etc.), including two-
sample t-test,33 analysis of variance (ANOVA),28 loadings of principle component analysis 
(PCA),34 and orthogonal partial least squares-discriminant analysis (OPLS-DA).15 
Compared with the above reported models, our method presents the following unique 
advantages: 1) SCMS based experiments allow for recognition of heterogeneous cells with 
different phenotypes. 2) Minimum sample preparation enables metabolomic signatures of 
live cells to be captured through online and in situ measurements. 3) Constructed ML 
models provide rapid results, which facilitates their potential translational applications 
towards future point-of-care (POC)35 prognostic assays. 4) Because our methods utilized a 
variety of cellular metabolites other than metabolic biomarkers alone, the model predictive 
accuracy is significantly improved (p-value < 0.05, from Welch’s one-tail t-test) compared 
with other models utilizing biomarkers discovered through two-sample t-test or PCA 
loading plot. As a complementary approach to identify discovered biomarkers at the 
population level, LC-MS/MS was performed and a total number of 28 biomarkers were 
identified. These results can potentially benefit future targeted studies, although not all 
discovered biomarkers can be identified possibly due to rapid metabolite turnover during 
cell lysis.7 In addition, we validated our methods using cells prepared from different batches 
to obtain comparable results. Although the cultured CML cells were used as the model in 
the current study, our method can be potentially used towards future prediction and 
prognosis of patient derived samples. However, because the clinical samples are rather 
complex, additional procedures for sample preparation are necessary. For example, 
heterogenous cells obtained from bone marrow biopsy in clinic need to be firstly purified, 
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followed by enrichment of leukemic cells using standard protocols including centrifugation 
and flow cytometry analysis36 prior to the SCMS experiments (~ 30 s/cell) and ML 
predictions of drug-resistant phenotypes. 
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Chapter 5: Towards Early Monitoring of Chemotherapy-induced Drug Resistance Using 
Single Cell Metabolomics and Machine Learning 
 
5.1. Introduction 
Although broadly recognized as a treatment approach to cancer, chemotherapy suffers from poor 
outcomes in the clinic1 due to the fact that the efficacy of a variety of chemotherapeutic agents is 
hindered by drug resistance through complex mechanisms (e.g., decreased drug uptake,2 
increased cellular detoxification,3 oncogene mutation,4 and other mechanisms5,6). The reduced 
chemotherapeutic efficacy renders treatment failure and relapse of malignancy. There are two 
general types of drug resistance: primary drug resistance, which denotes intrinsic resistance to 
chemotherapeutics prior to treatment due to genetic and epigenetic factors;7 and acquired drug 
resistance, which refers to the one that adapts and evolves upon treatment pressure.8 Recent 
evidence showed that the drug resistance observed following a chemotherapy may be due to a 
combination of both types.5,9 Despite in-depth mechanistic studies conducted to fundamentally 
enhance our understanding of drug resistance, a variety of approaches have been reported to 
monitor chemotherapy-induced drug resistance. These methods include well-established 
procedures (e.g., clinically applicable imaging-assisted tissue biopsy10,11) and development-stage 
techniques (e.g., fluorescence-labeled12 or nanoparticle-bound13 drug monitoring, liquid biopsy,14 
resistance-related protein monitoring,15 integral cell response monitoring,16 and real-time 
monitoring using optofluidic chips17). However, three major limitations still exist. First, a vast 
majority of reported approaches evaluate drug resistance based on cell populations, whereas the 
molecular information of tumor cell heterogeneity, which plays a key role in cancer progression, 
is inevitably lost.18 Second, depending on the type of drug resistance, most methods need a 
69 
 
lengthy monitoring period (e.g., one19 to several months20 after chemotherapy) for reliable 
results, exposing patients to ineffective chemo-treatment and accompanied toxicity.21 Third, 
some methods require isolating tumor cells from their native biological microenvironment, 
leading to altered cellular metabolism and biophysical properties.22 Thus, it is needed to develop 
new analytical approaches capable of monitoring early treatment-stage chemotherapy-induced 
drug resistance of single cancer cells in their native states. 
 
To address these limitations, we have previously reported a method using single cell mass 
spectrometry (SCMS) experiments combined with machine learning (ML) data analysis to obtain 
metabolomic information of live individual cells, and predicted cells with primary drug 
resistance (i.e., cell adhesion-mediated drug resistance) before drug intervention.23 In this current 
work, we further developed an analytical approach to monitor different degrees of 
chemotherapy-induced drug resistance of live cancer cells after drug exposure.  
 
5.2. Experimental Section 
5.2.1. Single-probe single cell metabolomics and cytotoxic assays. In our approach, we 
coupled the Single-probe,24-29 a miniaturized and multifunctional device, to an in-house 
developed SCMS platform (Figure 5.1A) to perform metabolomic analysis at the single cell level 
(i.e., single cell metabolomics). Such online and in situ data acquisition allows for metabolomic 
signatures of individual cells to be captured in near native biological status with minimum 
metabolite turnover (Figure 5.1B).30 Human colon cancer cell line, HCT-116, was selected as a 
model system to demonstrate our method. Particularly, we exposed HCT-116 cells to low-
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concentration irinotecan (1 µM), a topoisomerase I (Topo I) inhibitor widely used in 
chemotherapies,31 to mimic chemo-treatment, followed by sequentially monitoring the temporal 
change of cellular metabolomic profiles induced by drug exposure. Typically, SCMS 
experiments were performed using cells in three different groups: control (no drug exposure; n = 
94), short-time drug exposure (1 µM for 10 days; n = 67), and long-time drug exposure (1 µM 
for 20 days; n = 70). Meanwhile, we measured the 50% inhibition concentration (IC50 at 72 h) of 
cells using cytotoxicity assay (i.e., MTT assay) to determine chemotherapy-induced drug 
resistance of cells at each time point (Figure 5.1C). We then referred to the resistance index (RI 
= IC50 drug-resistant cell/IC50 parental cell), a widely accepted standard to quantify drug resistance in 
clinical research,32 as a reference of the degree of drug resistance at the population level.   
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Figure 5.1. (A) SCMS data acquisition performed on an in-house developed SCMS platform 
with key components labeled. (B) Sampling a single cell using the Single-probe device. The 
contour of the Single-probe is drawn as visual guides. (C) Cytotoxicity measurements of HCT-
116 cells exposed to irinotecan for 72 h.  
 
5.2.2. SCMS metabolomics and statistical analysis. Obtained SCMS metabolomic datasets 
containing three groups of single cells (i.e., control, 10-day, and 20-day drug exposure) were 
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subjected to a comprehensive data pre-treatment procedure, including background subtraction, 
noise removal, intensity normalization, peak alignment, and selection of common species, to 
extract cellular metabolomic information from the raw data matrix. Pre-treated SCMS 
metabolomic datasets were subsequently subjected to dimensionality reduction using partial least 
square-discriminant analysis (PLS-DA),33 and metabolomic profiles of individual cells were 
intuitively visualized in the 2D space. In addition, univariate analysis such as analysis of 
variance (ANOVA) was performed to compare the relative ion intensities of detected cellular 
species among three groups, and metabolic biomarkers that are significantly different in 
abundance among all examined groups were further discovered. 
5.2.3. Machine learning. In addition to intuitive visualization of cellular metabolomic profiles 
using multivariate approach (i.e., PLS-DA), reliable mathematical models are imperative to 
monitor the chemotherapy-induced drug resistance by predicting the degree of possessed drug 
resistance (e.g., no, low, or high resistance) of single cells during chemo-treatment. Therefore, 
we applied ML methods to construct models that can learn the underlying patterns of the 
obtained SCMS datasets, and further predict drug-resistant cells based on their cellular 
metabolomic profiles. Three ML methods were utilized in our studies: random forest (RF) that 
outputs the most voted decision in the ensemble model,34 artificial neural network (ANN) that 
optimizes model prediction by modifying the network configuration between nodes and layers,35 
and multinominal penalized (i.e., elastic net) logistic regression (LR) that predicts the categorical 
outcomes by maximizing the likelihood logistic function while minimizing less contributing 
variables36. Typically, 80% of single cells were randomly selected from the obtained SCMS 
datasets as the training set to construct a ML model, whereas the remaining cells were used as 
the testing set to evaluate the predictive accuracy. Each model was evaluated using five 
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independent predictions followed by a 5-fold cross-validation (CV) to avoid model bias.37 The 
model construction, validation, and evaluation were performed using an in-house developed 
script. 
 
5.3. Results and Discussion 
5.3.1. Development of chemotherapy-induced drug resistance. Through MTT measured IC50 
values of cells in three different groups (Figure 5.1C), we defined three levels of chemotherapy-
induced drug resistance, i.e., none (RI = 1), low (RI = 1.9), and high (RI = 3.6), using cells in the 
control group (no drug exposure), 10-day, and 20-day drug exposure groups, respectively.38 The 
increased drug resistance is likely associated with a variety of drug-resistant mechanisms,31 and 
can catastrophically hinder the drug efficacy of irinotecan in chemotherapies. It is also worth 
noting that the MTT readouts can only be used as a reference, as the cell-to-cell heterogeneity 
was masked by such population-level measurements. 
Table 1. Relative standard deviation (RSD) obtained from MS measurements of standard 
solution and single cells. 
Origin m/z Species RSD 
Standard Solution* 
760.5856 [PC(34:1) + H]+ 20.7% 
782.5676 [PC(34:1) + Na]+ 20.4% 
SCMS Datasets** 
756.5462 [PC(32:0) + Na]+ 68.9% 
760.5820 [PC(34:1) + H]+ 125.9% 
780.5457 [PC(34:2) + Na]+ 79.9% 
782.5616 [PC(34:1) + Na]+ 68.1% 
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808.5798 [PC(36:2) + Na]+ 75.2% 
810.5947 [PC(36:1) + Na]+ 65.8% 
 *RSD was caculated based on 10 independent measurements using two different Single-probes. 
**RSD was caculated based on measurements of 231 single cells possessing no, low and high 
ADR in the SCMS datasets. 
 
5.3.2. Temporal Change of Cellular Metabolomic Profiles. To study the change of cellular 
metabolomic profiles induced by drug exposure, we performed PLS-DA33 for the SCMS 
datasets, and evaluated the potential issues of model overfitting using a 10-fold CV39 (i.e., 
through 10 iterative model construction and predictions). As shown in Figure 5.2, our PLS-DA 
model generated an excellent cross-validated predictive ability (Q2 > 0.9), indicating no 
overfitting (Q2 > 0.5).40 In addition, 46% of total data variance can be explained by the first two 
dominating principal components. Despite cell heterogeneity reflected by the spatial distribution 
of data points,41,42 the discrimination between the “none” and “high” groups is evident, 
representing a significant influence of long-time drug exposure on the cellular metabolism.43 
However, the “low” group partially overlaps with the other two groups. Such overlapped 
distribution is likely attributed to heterogeneous metabolic response of individual cells to the 
drug exposure at the early treatment stage. We further evaluated the influence of technical 
variance (i.e., fluctuation of ion intensities due to technical factors of SCMS experiments) and 
biological variance (i.e., variation in cellular metabolomic profiles due to cell heterogeneity and 
drug exposure) on the established PLS-DA model. First, we used two different Single-probes to 
sequentially measure a standard lipid solution (1 µM of PC(34:1)), and calculated the relative 
standard deviation (RSD) two adducts, [PC(34:1) + H]+ (m/z 760.5856) and [PC(34:1) + Na]+ 
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(m/z 782.5676). The results represent the magnitude of technical variance44,45 during the data 
acquisition using different probes. Second, we calculated the RSD of a variety of identified 
cellular species, including [PC(34:1) + H]+ and [PC(34:1) + Na]+, from the SCMS datasets, 
representing the combination of technical and biological variance.44,45 Last, we compared the 
technical and biological variance as shown in Table 1. Evidently, the RSDs obtained from the 
standard solution (~20%) are significantly lower than those from the single cells (> 65%, i.e., > 3 
fold of increment). Assuming that the technical variance is similar among all SCMS 
experiments, the biological variance among individual cells is significant, eliminating the 
possibility that the observed group discrimination in the PLS-DA score plot is merely due to 
technical variance. However, the relation between two major factors (i.e., cell heterogeneity and 
drug exposure) that could induce biological variance is complex.42,46,47 Future experiments are 
needed to illustrate the underlying biological principals, however, these goals are beyond the 
scope of this study. 
76 
 
 
Figure 5.2. PLS-DA score plot of the SCMS datasets. Cellular metabolomic profiles 
corresponding to three groups of single cells possessing no (“None”, colored in blue), low 
(“Low”, colored in green) and high (“High”, colored in red) drug resistance are intuitively 
visualized in 2D space. 
 
5.3.3. Monitoring chemotherapy-induced drug resistance using ML models. RF, ANN, and 
penalized LR have been applied to conventional untargeted metabolomic research, such as 
identification of detected metabolites through liquid chromatography-mass spectrometry (LC-
MS),48 prediction of chromatographic retention time,49 and evaluation of metabolic changes.50 
These approaches were employed in our study to monitor chemotherapy-induced drug resistance 
by predicting the degrees of drug resistance (i.e., “none”, “low”, or “high”) of single cells based 
on established models. The predictive accuracy of each model was reported (Table 2) using the 
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confusion matrix.  Our models generated excellent predictive accuracy (97.4% ± 1.8%, 97.4% ± 
2.8% and 97.4% ± 2.3% for the RF, ANN and penalized LR model, respectively) compared with 
previously reported models in LC-MS metabolomic studies, in which relatively smaller numbers 
of measurements (e.g., ~100)51,52 were performed. Less-than-perfect (100%) predictive accuracy 
was present in our models possibly due to heterogenous cellular response to the drug pressure. 
Our results demonstrated the predictive power of ML models, particularly for analysis of subtle 
differences in cellular metabolomic profiles among multiple groups (e.g., as shown in Figure 
5.2). Notably, the predictive accuracies of those three models were comparable (p > 0.99 from 
Welch’s two-tail t-test) on the testing set, indicating their capability and reliability to monitor 
early-stage chemotherapy-induced resistance at the single cell level.  
 
5.3.4. Model Comparison. Metabolic biomarkers are of the great interest to conventional LC-
MS metabolomic studies, and they were frequently discovered and used to monitor drug 
resistance.53,54 Therefore, we carried out a systematic comparison of the performance (i.e., 
predictive accuracy) between models based on SCMS datasets and those utilizing metabolic 
biomarkers. A variety of criteria (e.g., statistical tests,55 loading plots of multivariate analysis,56,57 
or variable importance58) have been generally used for biomarker discovery in other 
metabolomic research. In our studies, biomarkers selection was carried out using ANOVA, 
loadings of principal component analysis (PCA), and variable importance (VI) measured by 
mean decrease accuracy (MDA),59 a value representing the contribution of a variable to the 
group separation. Different numbers of biomarkers were discovered using the above three 
methods: 24 from ANOVA (metabolites with ANOVA p-value < 0.05 and post-hoc p-value < 
0.05 between each compared groups); 22 from PCA loadings (metabolites with highest PC1 and 
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PC2 loading scores); and 15 from VI (top-15 metabolites with the highest MDA obtained from 
the RF model constructed on SCMS datasets).58 The number of variables in each dataset is 
different, with some metabolites mutually or exclusively discovered as biomarkers by the 
selection criterion (Figure 5.3). For example, seven metabolites were mutually regarded as 
biomarkers by all selection criteria, 20 metabolites were exclusively discovered under a specific 
selection criterion, and 41 metabolites in the SCMS datasets were not selected as biomarkers by 
any of the criterion. 
 
Figure 5.3. Venn diagram of the number of variables (metabolites) in each dataset, including the 
SCMS dataset (brown) and other subsets consisting of dicovered metabolic biomarkers through 
ANOVA (red), PCA loadings (green) and variable importance (VI, blue). 
 
We subsequently used these biomarkers discovered from different approaches and all 
metabolites included in the SCMS dataset to construct ML models using the RF, ANN and 
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penalized LR algorithms, and then evaluated the performance of these models (Table 2). 
Generally, all trained ML models exhibited excellent predictive accuracy on the testing set, 
despite that different groups of metabolites were utilized for model construction. Therefore, they 
all demonstrated the potential of our method towards prediction of drug-resistant cells in a rapid 
(< 30 s computing time in model construction) and reliable (> 94.9% predictive accuracy) 
fashion. On the other hand, the computing time for ML models based on biomarkers is less than 
the model based on SCMS datasets, likely due to fewer number of variables included.  
Table 2. Predictive accuracy of RF, ANN and penalized LR models based on SCMS datasets and 
biomarkers discovered using different criteria. 
Datasets 
Predictive 
Accuracy 
(RF) * 
Error 
RateRF** 
Predictive 
Accuracy 
(ANN) * 
Error 
RateANN** 
Predictive 
Accuracy 
(LR) * 
Error 
RateLR** 
SCMS 
97.4% ± 
1.8% 
2.2% 
97.4% ± 
2.8% 
2.1% 
97.4% ± 
2.3% 
3.5% 
ANOVA 
97.4% ± 
1.8% 
3.0% 
97.4% ± 
1.8% 
4.3% 
98.7% ± 
1.2% 
3.0% 
PCA 
Loadings 
97.9% ± 
1.5% 
4.3% 
95.7% ± 
2.6% 
5.7% 
94.9% ± 
2.4% 
5.2% 
VI 
96.2% ± 
1.0% 
3.5% 
98.3% ± 
1.8% 
1.7% 
98.7% ± 
1.9% 
1.7% 
*Predictive accuracy of single cells possessing no, low and high ADR was calculated from five 
independent predictions (average ± standard deviation). 
**Error rate was estimated using a 5-fold CV in each model. 
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5.3.5. Multi-class ROC Analysis. Despite the predictive accuracy, receiver operating 
characteristic (ROC) analysis was routinely conducted for classification models in LC-MS 
metabolomic studies,36 and the area under curve (AUC) was utilized to evaluate the classification 
capability, which is a complimentary measurement of performance in a diagnostic model.52,60 In 
our study, we conducted multi-class ROC analysis,61 a generalized form of traditional binary 
ROC analysis, to evaluate the classification capability of different ML models (Figure 5.4). 
Specifically, two pairs of data, i.e., one group of cells (e.g., “none”) and the other group 
consisting of all remaining cells (e.g., pooled “Low” and “High”), were used to calculate an 
AUC. This type of calculation was repeated on the other two groups of cells (e.g., “Low” and 
“High”), and the final results were reported as an averaged AUC (i.e., AUC). As a result, all 
models showed outstanding62 classification capability (AUC > 0.99) in predicting the cell 
attributes among all groups, agreeing with our earlier findings of the excellent model predictive 
accuracy.  
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Figure 5.4. Multi-class ROC analysis of ML models including RF models constructed on the (A) 
SCMS datasets, (B) ANOVA subset, (C) PCA loadings subset, (D) variable importance (VI) 
subset; ANN models constructed on the (E) SCMS datasets, (F) ANOVA subset, (G) PCA 
loadings subset, (H) VI subset; and penalized LR models constructed on the (I) SCMS datasets, 
(J) ANOVA subset, (K) PCA loadings subset, (L) VI subset .The model classification ability is 
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represented by the averaged area under curve (AUC) from three pairwise ROC analyses (e.g., 
“High” vs. pooled “Low” and “None”, etc.) in each model. 
 
5.3.6. Experimental Validation 
Our ML models were trained and evaluated using a collection of SCMS data measured on 
different days (batches). To further evaluate the robustness of these established ML models, we 
performed an experimental validation using additional batches of single cells. Specifically, the 
established ML models were directly used to predict the attributes of 37 single cells prepared and 
measured on a different day (nNone = 12, nLow = 14, nHigh = 11). As a result (Table 3), accurate 
(86.5% ± 3.3%) and rapid (~0.5 s) prediction was achieved using the RF model constructed on 
the SCMS datasets. Therefore, our methods demonstrated their potential to be directly adopted 
by other labs or clinics to monitor the degree of chemotherapy-induced drug resistance with 
minimum effort. However, the predictive accuracy of the ANN and penalized LR models are 
generally lower than the RF model, likely due to the nature of these ML algorithms, and future 
studies are still needed. In addition, ML models based on biomarkers selected using different 
criteria showed lower predictive accuracy compared with the corresponding model based on 
SCMS datasets using each of the ML algorithm (i.e., RF, ANN, and penalized LR). Although the 
reason for such compromised predictive accuracy is complex, it is likely due to the loss of 
information during biomarker selection (i.e., exclusion of non-biomarkers in the dataset). Similar 
trends were observed in our previous studies of predicting the primary drug resistance of cells 
using ML models based on metabolic biomarkers alone.23  
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Table 3. Predictive accuracy of established RF, ANN and penalized LR models for additional 
batch of SCMS data. 
Datasets 
Predictive Accuracy 
(RF)* 
Predictive Accuracy 
(ANN)* 
Predictive Accuracy 
(LR)* 
SCMS 86.5% ± 3.3% 75.1% ± 6.7% 65.9% ± 2.4% 
ANOVA 68.1% ± 1.2% 64.3% ± 7.3% 64.9% ± 1.9% 
PCA Loadings 68.7% ± 2.4% 68.7% ± 4.1% 63.2% ± 6.8% 
VI 68.1% ± 1.2% 52.4% ± 3.1% 54.1% ± 3.3% 
*Predictive accuracy of single cells possessing no, low and high ADR was calculated from five 
independent predictions (average ± standard deviation). 
 
5.4. Conclusion 
We reported an analytical approach combining single cell metabolomics with ML to monitor 
chemotherapy-induced drug resistance of cancer cells upon drug exposure. Three algorithms, 
including RF, ANN and penalized LR, were used to construct models based on datasets obtained 
through SCMS analysis of control and drug-exposed cancer cells. Following the model 
construction, we performed comprehensive evaluation such as 5-fold CV, predictive accuracy, 
and classification capability (i.e., ROC) to evaluate the performance of these ML models. Our 
results indicate that the RF model constructed using SCMS datasets could provide accurate 
(86.5% in predictive accuracy) and rapid (~0.5 s) predictions of individual cells possessing 
different levels of resistance (i.e., none, low, and high), and therefore, could be directly adopted 
by other labs for facile predictions. Although this current study was carried out using in vitro 
cancer cell lines, it can be potentially applied to early and real-time monitoring of chemotherapy-
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induced drug resistance of patient samples, provided that efficient isolation of malignant cells 
from clinical specimen is performed63 followed by SCMS measurements and ML predictions 
using an established model. Together with our previously reported method in predicting the 
primary drug resistance,23 we demonstrated novel approaches based on single cell metabolomics 
that can be potentially used for future point-of-care (POC)64 diagnostic assays in the clinic. 
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